Conference Coverage

Study finds AD accounts for hundreds of thousands of annual ED visits


 

REPORTING FROM AAD 18

– A new study finds that primary diagnoses of atopic dermatitis (AD) are made hundreds of thousands of times in United States emergency departments each year.

The numbers appear to be rising along with costs, researchers reported, and there are signs of disparities, with poorer people more likely to have an ED visit with a primary diagnosis of AD. The study was presented in a poster at the annual meeting of the American Academy of Dermatology.

Dr. Jonathan Silverberg of Northwestern University, Chicago

Dr. Jonathan Silverberg

“Access to outpatient dermatologic care needs to be improved,” study investigator Jonathan I. Silverberg, MD, PhD, of the department of dermatology, Northwestern University, Chicago, said in an interview. “Since AD is a chronic disorder that can be managed in the outpatient setting most of the time, it is likely that improved outpatient access and care and tighter control of AD would result in fewer [ED] visits and a considerable costs savings in the long run.”

He and his coauthor, Lauren Kwa, also with the department of dermatology at Northwestern, conducted the analysis to better understand the role of AD in emergency care. “Many AD patients experience severe, unpredictable flares and worsening chronic disease that warrant urgent treatment,” Dr. Silverberg said. “However, patients typically don’t have instant access to outpatient dermatological care and may be forced to turn to the urgent care setting.”

Pages

Recommended Reading

Systemic corticosteroids not recommended for long-term treatment of eczema
MDedge Family Medicine
Atopic march largely attributed to genetic factors
MDedge Family Medicine
Antihistamines still are prescribed inappropriately for atopic dermatitis
MDedge Family Medicine
Topical steroid reduces atopic dermatitis relapse in children
MDedge Family Medicine
VIDEO: Dupilumab or cyclosporine for treating atopic dermatitis?
MDedge Family Medicine
VIDEO: Off-label dupilumab finding a home in pediatric AD
MDedge Family Medicine
Upadacitinib calms itch, clears skin in moderate to severe atopic dermatitis
MDedge Family Medicine
Anti–IL-33 antibody stakes a first-in-class claim on moderate to severe atopic dermatitis
MDedge Family Medicine
VIDEO: With new therapies available, it’s the ‘decade of eczema,’ researcher says
MDedge Family Medicine
Dual kinase inhibitor performs well in its first safety, efficacy study for atopic dermatitis
MDedge Family Medicine